Skip to content
The Nexus
DossierENTITY

GLP-1 treatments

Coverage of GLP-1 treatments in the Nexus archive.

Earliest in view: Jun 30 · 12:25 UTCMost recent: Jun 30 · 12:25 UTC
Co-mentioned in this coverage
Medicareorganization1Eli Lillyorganization1Novo Nordiskorganization1Zepboundtopic1Foundayotopic1Wegovytopic1President Donald Trump’s administrationorganization1
Recent coverage
  • HEALTHJun 30 · 12:25 UTCWSOC ABC CHARLOTTE
    Medicare to cover GLP-1 treatments for weight loss

    Medicare will cover GLP-1 weight-loss treatments through a temporary pilot program starting July 1, allowing eligible participants to pay a $50 monthly co-pay. The program includes Eli Lilly’s Zepbound and Foundayo and Novo Nordisk’s Wegovy, with coverage ending by 2027 due to federal law restrictions. Eligibility requires a BMI of 35 or higher (or 30 with specific health conditions), and prior authorization is needed.